ArticlemBio2021
Structural Characterization of Diazabicyclooctane β-Lactam "Enhancers" in Complex with Penicillin-Binding Proteins PBP2 and PBP3 of Pseudomonas aeruginosa.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Calciphylaxis complicated by NDM-1-producing Pseudomonas aeruginosa: first experience with cefepime-zidebactam alongside phage therapy in the USA.The Lancet. Infectious diseases · 2026Review
- The global epidemiology and treatment of metallo-β-lactamase-producing gram-negative pathogens.JAC-antimicrobial resistance · 2026Review
- Distinctive Lacritin Cleavage-Potentiated Bactericidal Alteration of thebioRxiv : the preprint server for biology · 2026Article
- Cefepime Combined with Late-Generation β-Lactamase Inhibitors: Mechanisms of Action, In Vitro Activity, PK/PD Characteristics, Clinical Evidence and Resistance Mechanisms.Antibiotics (Basel, Switzerland) · 2026Review
- Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Green Fabrication of Silver Nanoparticles, Statistical Process Optimization, Characterization, and Molecular Docking Analysis of Their Antimicrobial Activities onto Cotton Fabrics.Journal of functional biomaterials · 2024Article
- Cefiderocol susceptibility endows hope in treating carbapenem-resistantRSC advances · 2024Article
- Pathohistological Changes in the Gastric Mucosa in Correlation with the Immunohistochemically Detected Spiral and Coccoid Forms ofMicroorganisms · 2024Article
- Drug Discovery in the Field of β-Lactams: An Academic Perspective.Antibiotics (Basel, Switzerland) · 2024Review
- Using host-mimicking conditions and a murine cutaneous abscess model to identify synergistic antibiotic combinations effective againstFrontiers in cellular and infection microbiology · 2024Article
- Penicillin-binding protein (PBP) inhibitor development: A 10-year chemical perspective.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Repurposing Amphotericin B: anti-microbial, molecular docking and molecular dynamics simulation studies suggest inhibition potential of Amphotericin B against MRSA.BMC chemistry · 2023Article
- Design and Synthesis of Novel Antimicrobial Agents.Antibiotics (Basel, Switzerland) · 2023Review
- Combined Structural Analysis and Molecular Dynamics Reveal Penicillin-Binding Protein Inhibition Mode with β-Lactones.ACS chemical biology · 2022Article
- Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition.Molecules (Basel, Switzerland) · 2022Review
- Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam.Antimicrobial agents and chemotherapy · 2022Article
- Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.Antimicrobial agents and chemotherapy · 2022Review
- Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.Microbiology spectrum · 2022Article
- Biochemical exploration of β-lactamase inhibitors.Frontiers in genetics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Malligarjunan RajavelDepartment of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.
Vijay KumarDepartment of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-2741-8891
Ha NguyenDepartment of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.
Jacob WyattDepartment of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.
Steven H MarshallLouis Stokes Cleveland Veteran's Affairs Medical Center Research Service, Cleveland, Ohio, USA.
Krisztina M Papp-WallaceLouis Stokes Cleveland Veteran's Affairs Medical Center Research Service, Cleveland, Ohio, USA.ORCID 0000-0002-9976-7898
Prasad DeshpandeWockhardt Research Centre, Aurangabad, India.
Satish BhavsarWockhardt Research Centre, Aurangabad, India.
Ravindra YeoleWockhardt Research Centre, Aurangabad, India.
Sachin BhagwatWockhardt Research Centre, Aurangabad, India.
Mahesh PatelWockhardt Research Centre, Aurangabad, India.
Robert A BonomoDepartment of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X
Focco van den AkkerDepartment of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA focco.vandenakker@case.edu.ORCID 0000-0001-9210-3565
Case Western Reserve University · USWockhardt (India) · INLouis Stokes Cleveland VA Medical Center · US
Funding
X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Sean McSweeney · 2019 to 2026
$38.6MX-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6MThe J. Craig Venter Institute Genome Center for Infectious DiseasesU19AI110819 · NIAID · J. CRAIG VENTER INSTITUTE, INC. · PI TAN, GENE · 2014 to 2018
$29.7MUnderstanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS U19 AI110819NIGMS NIH HHS P30 GM133893NIGMS NIH HHS P41 GM103393
Abstract
Multidrug-resistant (MDR) pathogens pose a significant public health threat. A major mechanism of resistance expressed by MDR pathogens is β-lactamase-mediated degradation of β-lactam antibiotics. The diazabicyclooctane (DBO) compounds zidebactam and WCK 5153, recognized as β-lactam "enhancers" due to inhibition of
Indexed as
Anti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsBridged Bicyclo CompoundsCrystallizationCyclooctanesMicrobial Sensitivity TestsOctanesPenicillin-Binding ProteinsPiperidinesProtein BindingPseudomonas aeruginosaAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsBridged Bicyclo CompoundsCyclooctanesOctanesPenicillin-Binding ProteinsPiperidinesWCK 5153zidebactamantibiotic resistancepenicillin-binding proteinsPseudomonas aeruginosastructural biology
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.